Concerning non-endometrioid carcinomas, altered p53 expression is often accompanied by somatic mutations in Protein Phosphatase 2 Scaffold Subunit Aalpha, FBXW7, Speckle-type POZ protein, Chromodomain Helicase DNA Binding Protein 4 and TATA-Box Binding Protein Associated Factor 1 genes, while Erb-B2 Receptor Tyrosine Kinase 2, MYC proto-oncogene, bHLH transcription factor, CCNE1and CDKN2A are amplified or overexpressed [15]. The gene discussed is CDKN2A; the disease is endometrioid adenocarcinoma.